biotech · Acute Myeloid Leukemia · Acute Myelogenous Leukemia in Relapse · APTOF
Aptose Biosciences
Aptose Biosciences clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 32
- Programs
- 8
- Drugs
- 1
- Patents
- 7
Aptose Biosciences projects
8 ClinicalTrials.gov programs sponsored by Aptose Biosciences.
Aptose Biosciences has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Virulizin®
Aptose Biosciences
Pancreatic Cancer
1 trial -
GTI-2040
Aptose Biosciences
Carcinoma, Renal Cell
1 trial -
GTI-2040
Aptose Biosciences
Acute Myeloid Leukemia
1 trial -
Tuspetinib
Aptose Biosciences
Leukemia, Myeloid, Acute
1 trial -
APTO-253
Aptose Biosciences
Acute Myelogenous Leukemia in Relapse
1 trial -
CG-806
Aptose Biosciences
Acute Myeloid Leukemia
1 trial -
CG-806
Aptose Biosciences
Chronic Lymphocytic Leukemia
1 trial -
LOR-253 HCl
Aptose Biosciences
Advanced or Metastatic Solid Tumours
1 trial
Frequently asked questions
How many clinical projects does Aptose Biosciences have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.